Cancer

February 21, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/February/2018, 6.00 am

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/February/2018, 6.00 am https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-GRHL3-and-lnCRNA-GAS5-and-promote-metastatic-suppression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-GRHL3-and-lnCRNA-GAS5-and-promote-metastatic-suppression.jpg February 21, 2018 February 21, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 19, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors RECK1 and CADM1 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 19/February/2018, 11.54 pm

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors RECK1 and CADM1 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 19/February/2018, 11.54 pm https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-RECK1-and-CADM1-and-promote-metastatic-suppression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-RECK1-and-CADM1-and-promote-metastatic-suppression.jpg February 19, 2018 February 19, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 16, 2018

Molecular therapy for Cancer: A therapeutic mix encompassing N-Acetyl Cysteine (NAC), SAHA, Amitriptyline, 17-DMAG and Rosuvastatin (NSADR) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 16/February/2017, 11.04 pm

Molecular therapy for Cancer: A therapeutic mix encompassing N-Acetyl Cysteine (NAC), SAHA, Amitriptyline, 17-DMAG and Rosuvastatin (NSADR) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 16/February/2017, 11.04 pm https://genomediscovery.org/wp-content/uploads/2018/02/NSADR-inhibits-cancer-progression-through-induction-of-REV-ERB.jpg3_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/NSADR-inhibits-cancer-progression-through-induction-of-REV-ERB.jpg3_.jpg February 16, 2018 February 16, 2018

Introduction:What they say: A recent study from Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA and Laboratory of Genetics, Salk Institute for Biological Studies, La…

February 15, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/February/2018, 10.59 pm

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/February/2018, 10.59 pm https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-TPM-and-TAp63-and-promote-metastatic-suppression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-TPM-and-TAp63-and-promote-metastatic-suppression.jpg February 15, 2018 February 15, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 14, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors TPM1 and TAp63 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/February/2018, 11.20 pm

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors TPM1 and TAp63 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/February/2018, 11.20 pm https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-TPM-and-TAp63-and-promote-metastatic-suppression.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-TPM-and-TAp63-and-promote-metastatic-suppression.jpg1_.jpg February 14, 2018 February 14, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 4, 2018

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 5/February/2018, 12.07 am

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 5/February/2018, 12.07 am https://genomediscovery.org/wp-content/uploads/2018/02/GDESSF-inhibits-GPX4-expression-and-promotes-sensitivity-to-drug-resistant-cancers.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/GDESSF-inhibits-GPX4-expression-and-promotes-sensitivity-to-drug-resistant-cancers.jpg February 4, 2018 February 4, 2018

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

Popular Post